glaxosmithkline

GlaxoSmithKline's (GSK) shares climbed 2.2% in pre-market trading after a majority of the U.S. Food and Drug Administration's panel voted to keep its controversial type 2 diabetes drug Avandia on the U.S. market, albeit with new restrictions. The diabetes drug already carries a black box label...

GlaxoSmithKline, whose diabetes drug Avandia is undergoing a safety review by the FDA, has agreed to pay about $460 million to resolve about 10,000 lawsuits from users of the drug, which can allegedly cause heart attacks and strokes.

GlaxoSmithKline's diabetes drug Avandia once again captured headlines Monday morning after two new studies linked it to heart attacks and other cardiovascular complications. The authors of the studies say the results should prompt the FDA to pull the drug from the market.

Entering February, a mixed picture on employment has developed: Job cuts in January reached their highest total since August, but still represent a 70% reduction from the same time a year ago, when they peaked at 241,749. What's going on?

He's young, charismatic, innovative and has got heart. At least that's the impression GlaxoSmithKline CEO Andrew Witty gives to the outside world. GSK is allowing free access to its library of 13,500 potential malaria treatments. Is he genuinely a do-gooder or just good at PR?

President Obama can't be pleased by the loss of a Democratic Senate seat which jeopardizes passage of his cherished health-care reform. The news, however, appears to have fueled a mini stock rally in the health-care and pharma sectors wary of how any reform would affect their businesses. The uptrend is expected to continue.

By many measures, this past decade was a downer. We experienced the dot-com bust, terrorism attacks, the Enron scandal, Bernie Madoff's Ponzi scheme, at least two wars and the Jonas Brothers. Oh, and lest I forget, one of worst financial crises in history. For anyone reading this,...

AstraZeneca (AZN) has had a good week with its anticlotting drug Brilinta (ticagrelor). It impressed many observers by announcing positive results of a late-stage head-to-head study and a mid-stage study for Brilinta, and on Thursday, it said it had filed for Food and Drug Administration approval....

The majority of Americans want to be vaccinated against swine flu, polls show. But unless you're in a high-risk group, such as expectant mothers, you may not get any vaccine anytime soon. In fact, the Centers for Disease Control and Prevention says the current tide of H1N1 influenza is likely to...

The U.S. may worry about having enough H1N1 vaccine to protect its population from swine flu, but at least it's getting precious doses. Many developing countries, which can't afford the sometimes expensive medication, don't have any at all. That may change soon. The U.K.'s GlaxoSmithKline (GSK)...